OKYO.L Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 May 2023 @ 11:35):

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom...

Stats
Today's Volume	19 575.00
Average Volume	538 135
Market Cap	23.22M
EPS	£0 ( 2023-12-28 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-1.400
ATR14	£0.371 (26.50%)

Volume Correlation

Long: 0.26 (neutral)

Short: -0.60 (weak negative)

Signal:(35.253) Neutral

OKYO Pharma Ltd Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

OKYO Pharma Ltd Correlation - Currency/Commodity

0.68
( moderate )

0.60
( weak )

0.00
( neutral )

-0.44
( neutral )

0.14
( neutral )

-0.77
( moderate negative )

OKYO Pharma Ltd Financials

Annual	2022
Revenue:	£0
Gross Profit:	£0 (0.00 %)
EPS:	£-0.00420

Q2	2021
Revenue:	£0.00
Gross Profit:	£0.00 (0.00 %)
EPS:	£-0.000591

Q1	2021
Revenue:	£0.00
Gross Profit:	£0.00 (0.00 %)
EPS:	£-0.000591

Q4	2020
Revenue:	£0.00
Gross Profit:	£0.00 (0.00 %)
EPS:	£-0.000591

Financial Reports:

No articles found.

OKYO Pharma Ltd

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.